| Description | Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells. |
| In vitro | Clivatuzumab 对胰腺导管腺癌（PDAC）表现出高度特异性，对正常及良性的非肿瘤胰腺组织几乎不表现出反应。尽管它对其他某些器官（如胃、结肠和肺）的腺癌反应有限（大约10%的样本）[1]。 |
| molecular weight | N/A |
| CAS | 1622075-09-5 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Gold DV, et al. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Mol Cancer. 2013 Nov 20;12(1):143. |